GIPL · XBRL financial data
Global Innovative Platforms financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (GIPL's year ends in late September)
| In thousands of dollars | Sep 30, 2021 | Sep 30, 2022 | †Sep 30, 2023 | Sep 30, 2024 | Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Research and development | — | — | — | 23 | 383 |
| General and administrative | 73 | 54 | 283 | 136 | 335 |
| Total operating expenses | 73 | 54 | 283 | 136 | 718 |
| Operating income (loss) | (73) | (54) | (283) | (136) | (718) |
| Other income (expense) | 0 | 0 | 0 | 0 | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | — |
| Net income (loss) | — | (54) | (283) | (136) | (718) |
| Earnings per share, basic USD per share | — | (0.08) | (0.46) | (0.01) | (0.02) |
| Earnings per share, diluted USD per share | — | (0.08) | (0.46) | (0.01) | (0.02) |
| Weighted average shares, basic thousands of shares | — | 619 | 619 | 26,626 | 39,369 |
| Weighted average shares, diluted thousands of shares | — | 619 | 619 | 26,626 | 39,369 |
- † Share count changed about 45x in the period ending 2023-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (GIPL's year ends in late September)
| In thousands of dollars | Sep 30, 2021 | Sep 30, 2022 | †Sep 30, 2023 | Sep 30, 2024 | Sep 30, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 48 | 0 | 0 | 18 |
| Accounts receivable | — | — | — | — | 0 |
| Total current assets | 0 | 48 | 0 | 0 | 199 |
| Property and equipment, net | 0 | 0 | 0 | 0 | 0 |
| Total assets | 0 | 48 | 0 | 0 | 199 |
| Accounts payable | 5 | 5 | 3 | 1 | 0 |
| Accrued liabilities | — | — | — | 0 | 10 |
| Total current liabilities | 29 | 130 | 364 | 33 | 12 |
| Total liabilities | 29 | 130 | 364 | 33 | 12 |
| Accumulated deficit | (64) | (118) | (401) | (537) | (1,255) |
| Total stockholders' equity | (29) | (83) | (364) | (33) | 188 |
| Total liabilities and equity | 0 | 48 | 0 | 0 | 199 |
| Common shares outstanding (cover page) thousands of shares | 619 | 619 | 27,841 | 36,245 | 46,754 |
- † Share count changed about 45x in the period ending 2023-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (GIPL's year ends in late September)
| In thousands of dollars | Sep 30, 2021 | Sep 30, 2022 | †Sep 30, 2023 | Sep 30, 2024 | Sep 30, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | — | (54) | (283) | (136) | (718) |
| Net cash from operating activities | 0 | (54) | (235) | (87) | (561) |
| Net cash from investing activities | 0 | 0 | 0 | 0 | (175) |
| Net cash from financing activities | 0 | 101 | 187 | 87 | 754 |
- † Share count changed about 45x in the period ending 2023-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Global Innovative Platforms | 244 | 51 | (134)* | 49.8M | 1.8 quarters | 10-QJun 30, 2026 |
| Interpace Biosciences | 2,688 | 9,131 | 98* | 27.7M | — | 10-QJun 30, 2026 |
| ENDRA Life Sciences | 1,740 | not reported | (928)* | 1.5M | 1.9 quarters | 10-QJun 30, 2026 |
| Bluejay Diagnostics | 9,599 | not reported | (1,499)* | 4.5M | 6.4 quarters | 10-QJun 30, 2026 |
| Stimcell Energetics | 6.9 | not reported | (109) | 21.1M | 0.1 quarters | 10-QAug 31, 2026 |
| LogicMark | 3,496 | 3,349 | 83* | 899,759 | — | 10-QJun 30, 2026 |
| INVO Fertility | 3,733 | 2,175 | (1,101)* | 2.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Nu-Med Plus | 5.4 | 0 | 1.1* | 83.5M | — | 10-QJun 30, 2026 |
| STRATA Skin Sciences | 7,912 | 9,292* | (239)* | 5.9M | 33.1 quarters | 10-KDec 31, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.